Clinical Trials

200 enrolled

Locoregional Recurrence

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

47 enrolled 17 charts

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

19 enrolled 10 charts

Breast Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

28 enrolled

Phase 3 Active not recruiting

ER-Positive Breast Cancer

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

1,473 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT03393845 2026-01-02

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

47 enrolled

Breast Neoplasms

NCT04762979 2026-01-02

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

44 enrolled

Phase 2 Not yet recruiting

Hormone Receptor Positive Breast Carcinoma

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

272 enrolled

Breast Cancer Metastatic

NCT06110793 2025-12-17

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1/2 Recruiting

49 enrolled

Breast Neoplasms

NCT04603183 2025-12-12

ABIGAIL

162 enrolled

Breast Cancer Metastatic

NCT02738866 2025-12-10

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

60 enrolled

Breast Neoplasms

NCT07117630 2025-12-05

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

20 enrolled

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07235618 2025-11-19

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

50 enrolled

Breast Neoplasms

NCT07180160 2025-11-18

ITHRAN

123 enrolled

Advanced Breast Cancer

NCT05608252 2025-10-29

VS-6766+Abema+Fulv in Met HR+/HER- BC

Phase 1/2 Recruiting

63 enrolled

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

220 enrolled 11 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

Phase 1 Not yet recruiting

HER2-positive Breast Cancer

NCT07163481 2025-09-16

SoGreat

12 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02958852 2025-09-10

ABC-SE

126 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating

NCT05625087 2025-08-20

SAFIR 03

162 enrolled

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

120 enrolled

Breast Neoplasms

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Breast Neoplasms

NCT00585507 2025-07-10

Efficacy and Safety of 500mg of Fulvestrant

40 enrolled

Breast Neoplasms

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

61 enrolled 12 charts

Breast Neoplasms

NCT00253422 2025-06-04

SoFEA

Phase 3 Completed

698 enrolled 19 charts

Breast Neoplasms

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT01441947 2025-05-25

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

68 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05054374 2025-05-23

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Phase 1/2 Completed

6 enrolled 4 charts

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

90 enrolled

Breast Neoplasms

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Phase 1 Completed

20 enrolled

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

Phase 4 Recruiting

300 enrolled

Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

18 enrolled

Phase 3 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT05207709 2025-04-29

HARMONIA

456 enrolled

Breast Neoplasms

NCT05536128 2025-04-17

Post-CDK

64 enrolled

Advanced Breast Cancer

NCT05816655 2025-03-18

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

202 enrolled

Breast Neoplasms

NCT04053322 2025-03-12

DOLAF

172 enrolled

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

NCT06856200 2025-03-04

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase NA Recruiting

36 enrolled

Advanced HR - Positive, HER2 - Negative Breast Cancer

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT06734533 2024-12-16

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Recruiting

80 enrolled